Anthelmin 230 mg/20 mg film-coated tablets for cats

- Praziquantel
- Pyrantel embonate

Authorised

Product identification

Medicine name:
Anthelmin 230 mg/20 mg film-coated tablets for cats
Anthelmin vet 230 mg / 20 mg tabletti, kalvopäällysteinen
Active substance:

- Praziquantel
- Pyrantel embonate

Target species:

- Cat

Route of administration:

- Oral use

Product details

Active substance and strength:

- Praziquantel
  20.00
  milligram(s)
  /
  1.00
  Tablet
- Pyrantel embonate
  230.00
  milligram(s)
  /
  1.00
  Tablet

Pharmaceutical form:

- Film-coated tablet

Withdrawal period by route of administration:

- Oral use

- Cat

Anatomical therapeutic chemical veterinary (ATCvet) codes:

- QP52AA51

Legal status of supply:

- Veterinary medicinal product subject to veterinary prescription except for some pack sizes

Authorisation status:

- Valid

Authorised in:

- Finland

Package description:

- (ID7) 100 Film-coated tablet: unspecified outer container with 10 Blister (Orientated PolyAmide; Aluminium; PolyVinyl Chloride) each with 10 Film-coated tablet, closed with Foil (Aluminium)
- (ID6) 50 Film-coated tablet: unspecified outer container with 5 Blister (Orientated PolyAmide; Aluminium; PolyVinyl Chloride) each with 10 Film-coated tablet, closed with Foil (Aluminium)
- (ID5) 30 Film-coated tablet: unspecified outer container with 3 Blister (Orientated PolyAmide; Aluminium; PolyVinyl Chloride) each with 10 Film-coated tablet, closed with Foil (Aluminium)
- (ID4) 10 Film-coated tablet: unspecified outer container with 1 Blister (Orientated PolyAmide; Aluminium; PolyVinyl Chloride) with 10 Film-coated tablet, closed with Foil (Aluminium)
- (ID2) 4 Film-coated tablet: unspecified outer container with 2 Blister (Orientated PolyAmide; Aluminium; PolyVinyl Chloride) each with 2 Film-coated tablet, closed with Foil (Aluminium)
- (ID1) 2 Film-coated tablet: unspecified outer container with 1 Blister (Orientated PolyAmide; Aluminium; PolyVinyl Chloride) with 2 Film-coated tablet, closed with Foil (Aluminium)

Additional information

Entitlement type:

- Marketing Authorisation

Legal basis of product authorisation:

- Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:

- KRKA tovarna zdravil d.d. Novo mesto

Marketing authorisation date:

- 22/11/2017

Manufacturing sites for batch release:

- KRKA tovarna zdravil d.d. Novo mesto
- TAD Pharma GmbH
- Krka-Farma d.o.o.
- Krka-Farma d.o.o.

Responsible authority:

- Finnish Medicines Agency

Authorisation number:

- 33767

Date of authorisation status change:

- 22/11/2017

Reference member state:

- Germany

Procedure number:

- DE/V/0160/001

Concerned member states:

- Austria
- Belgium
- Bulgaria
- Croatia
- Czechia
- Estonia
- Finland
- France
- Hungary
- Ireland
- Italy
- Latvia
- Lithuania
- Netherlands
- Poland
- Portugal
- Romania
- Slovakia
- Slovenia
- Spain
- United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Product information

Summary of Product Characteristics

English (PDF)
Published on: 14/02/2022
Download

Combined File of all Documents

English (PDF)
Published on: 14/06/2024
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Other languages (1)
Finnish (PDF)
Published on: 13/06/2024
Download
